Disease duration and hla-b27 positivity alter longterm retention rate of certolizumab pegol in patients with psoriatic arthritis

Koca, S. S.Pehlivan, Y.Akar, S.Senel, S.Karadeniz, H.Sosyal, O.Yazici, A.Yilmaz, S.Sagir, R. PiskinInanc, N.Karatas, A.Cetin, G. YildirimOnen, F.2024-06-272024-06-272021-06-010003-4967https://doi.org/10.1136/annrheumdis-2021-eular.2832https://hdl.handle.net/11452/42526Bu çalışma, 02-05 Haziran 2021 tarihleri arasında Montreal[Kanada]’da düzenlenen Annual European Congress of Rheumatology (EULAR)’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessScience & technologyLife sciences & biomedicineRheumatologyRheumatologyDisease duration and hla-b27 positivity alter longterm retention rate of certolizumab pegol in patients with psoriatic arthritisMeeting Abstract0006926253005591317131780Supplement110.1136/annrheumdis-2021-eular.2832